By acquiring the shares, Carl Zeiss AG underscores its clear commitment to Carl Zeiss Meditec AG and its strategic direction. As a major shareholder, Carl Zeiss AG stands firmly behind the company, demonstrating long-term support for Carl Zeiss Meditec AG and its continued growth through these additional share acquisitions.
Carl Zeiss AG stresses that, with the intended increase in its shareholding, it does not pursue any objectives beyond increasing its shareholding position. In particular, there are no plans to enter into a domination and profit transfer agreement or any other corporate agreement, nor to implement other structural measures, such as delisting or similar measures. With this acquisition of shares, Carl Zeiss AG pursues no plans to change the strategic direction of Carl Zeiss Meditec AG or its corporate structure.
Carl Zeiss AG continues to attach great importance to ensuring an adequate free float for Carl Zeiss Meditec AG. Carl Zeiss Meditec AG will also continue to have a broad shareholder base and ensure adequate tradability of its shares on the stock market. Against this backdrop, Carl Zeiss AG (including shares held indirectly through Carl Zeiss, Inc.) plans not to exceed 70% of the voting rights in Carl Zeiss Meditec AG.
The acquisition of shares is expected to be completed by the end of February 2027 and will be conducted exclusively on the stock market. The total volume of the planned purchases will not exceed 200 million euros. The timing and scope of the individual share acquisitions will be determined by prevailing market conditions. Carl Zeiss AG has commissioned an independent financial institution to purchase the shares. The commissioned financial institution makes its decisions independently and without influence from Carl Zeiss AG regarding the timing, scope, and price of the share acquisitions.
